<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01375998</url>
  </required_header>
  <id_info>
    <org_study_id>15328</org_study_id>
    <secondary_id>YAZ-DUI</secondary_id>
    <nct_id>NCT01375998</nct_id>
  </id_info>
  <brief_title>YAZ Post-marketing Surveillance in Japan</brief_title>
  <official_title>Drug Use Investigation of YAZ</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a regulatory post marketing surveillance in Japan, and it is a local
      prospective and observational study of patients who have received YAZ for dysmenorrhea. The
      objective of this study is to assess safety and efficacy of using YAZ in clinical practice. A
      total 3,000 patients will be recruited and followed 3 years since starting YAZ
      administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 9, 2011</start_date>
  <completion_date type="Actual">March 8, 2018</completion_date>
  <primary_completion_date type="Actual">December 5, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse drug reactions and sever adverse events</measure>
    <time_frame>During YAZ administration, up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in severity of dysmenorrhea at 6th cycles (28 days per cycle)</measure>
    <time_frame>Baseline and during YAZ administration, up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>During YAZ administration, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unpleasant physical symptoms collection</measure>
    <time_frame>Baseline and during YAZ administration, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unpleasant psychological symptoms collection</measure>
    <time_frame>Baseline and during YAZ administration, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic drug for dysmenorrhea</measure>
    <time_frame>During YAZ administration, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL survey using Short-Form 36-Item Health Survey (SF-36)</measure>
    <time_frame>Baseline and at 6th - 8th cycles (28 datys per cycle)</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3273</enrollment>
  <condition>Dysmenorrhea</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EE20/DRSP(YAZ, BAY86-5300)</intervention_name>
    <description>Patients in daily life treatment receiving YAZ for dysmenorrhea.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The target population of this study is patients who have received a prescription of YAZ on
        the basis of the decision of the treating gynecologist. The study is expected to collect
        data of 3,000 patients in about 300 gynecological practices in Japan.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who received YAZ for dysmenorrhea Additional criteria for QOL questionnaire

          -  Patient informed consent

        Exclusion Criteria:

          -  Patients who are contraindicated based on the product label Additional criteria for
             QOL questionnaire

          -  Six months or less after treatment of estrogen or estrogen combination drug
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2011</study_first_submitted>
  <study_first_submitted_qc>June 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2011</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>YAZ</keyword>
  <keyword>Dysmenorrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

